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biplane high-speed cinefluoroscopy of implanted mitral
annular radiopaque markers with 3-dimensional echo data
would constitute the ideal validation benchmark, but such
investigations have not been carried out to date, either in ani-
mals or in man. To this end, our laboratory, with the necessary
video processing and coupled computer systems, would be
pleased to collaborate with any serious investigator who has
the capability to insert multiple miniature markers in the
mitral anulus in patients and obtain high-quality biplane cine-
fluoroscopic images postoperatively.
Until that day arrives, the quest for the Holy Grail con-
cerning human mitral valve pathophysiology will remain
unfulfilled; furthermore, in my opinion, until more quantita-
tive, validated 3-dimensional data are available, all 3-
dimensional echocardiographic estimates of mitral valve
area and fractional area reduction should be interpreted cau-
tiously, because they may represent gross overestimates and
reflect the motion of structures other than the mitral anulus
per se.
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A word of caution in extrapolating the riluzole
spinal cord injury protective effects obtained in a
rabbit model under ketamine anesthesia
To the Editor:
We read with great interest the excellent article titled
“Riluzole Prevents Ischemic Spinal Cord Injury Caused by
Aortic Crossclamping” by Lang-Lazdunski and associates (J
Thorac Cardiovasc Surg 1999;117:881-9). We do not doubt
the protective effects exhibited by riluzole, and we believe
this article is a significant contribution to central nervous sys-
tem protection, for which the authors are to be congratulated.
However, we would like to reiterate a point that was raised
recently concerning an article on memantine.1,2
The authors’ anesthetic included 50 mg/kg of ketamine.
Ketamine is an N-methyl-D-aspartate antagonist and known to
confer significant protection of the central nervous system
against ischemia.3,4 Since the mechanisms of action of keta-
mine and riluzole seem to be different, the likelihood of
effects being even potentiating and not only additive are real.
Thus the observed protective effects of riluzole were the result
of the effects of riluzole by itself in addition to those con-
tributed by ketamine, but their relative roles are unknown. For
definitive assessment of the protective effects of riluzole
alone, a group of rabbits anesthetized with nonprotective con-
centrations of volatile agents only, without ketamine or barbi-
turates, is essential before the data, concerning particularly the
ischemic time, can be extrapolated to human application since
ketamine is not usually used in adult human clinical practice.
We5 have found, in a similar model but without using keta-
mine, that neurologic functional recovery objectively evaluat-
ed 6 hours after reperfusion accurately reflects the subse-
quent outcome at 24 hours. We wonder whether the authors
made neurologic score evaluations early after reperfusion and
whether neurologic functional improvement was noticed
between 24 hours and 120 hours in those observed for more
than 24 hours.
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Reply to the Editor:
We thank Miyamoto and Miyamoto for their interest in our
recent article.1 It is a fact that ketamine is a widely known N-
methyl-D-aspartate receptor antagonist that has demonstrated
neuroprotective properties in vitro and in vivo.2 Therefore the
observed neuroprotective effect in our study is the result of
ketamine and riluzole effects. Ketamine has been widely used
by most investigators working with the rabbit model of spinal
cord ischemia, with minor spinal cord protection afforded by
this drug.2,3 In our study, all rabbits received the same dose of
ketamine, with huge differences in neurologic recovery
among experimental groups. Thus, although the potentiating
effect of ketamine cannot be ruled out, it is unlikely that this
drug by itself could account for the dramatic differences in
neurologic recovery among experimental groups. For defini-
tive assessment of the neuroprotective effects of riluzole, we
have performed a new study with a spinal cord ischemia
model in the rat.4 All animals were anesthetized with
halothane 1.5% only, and they received riluzole before aortic
crossclamping and at the onset of reperfusion. Rats were
allowed to recover for 24 (n = 15), 48 (n = 10), or 96 hours
(n = 5). In this study, riluzole again prevented neuronal necro-
sis and apoptosis and cytoskeletal proteolysis.
Regarding neurologic recovery of rabbits, we did not
observe worsening of neurologic status in riluzole-treated
rabbits between 24 and 120 hours after the operation. Rabbits
were scored at 6 hours, 24 hours, and then daily. Riluzole-
treated rabbits typically began to recover motor and sensory
function between 6 and 24 hours after the operation, whereas
control rabbits did not. Neurologic scoring before 6 hours
would have been inappropriate considering the anesthetic
properties of riluzole. In our recent study, control rats
remained severely paraplegic after the operation, whereas
riluzole-treated rats began to recover at 6 hours and had either
completely normal neurologic function or a mild to moderate
deficit up to 96 hours postoperatively.
This result is of importance because some neuroprotective
drugs can modify the early recovery but finally fail to alter
the mid-term and late recovery after spinal cord ischemia.5
Riluzole, however, not only has a transient effect, but also
may really and consistently prevent spinal cord ischemic
injury when given before aortic crossclamping.
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Measurement of chest wall forces on coughing with
the use of human cadavers
To the Editor:
We read with interest the recent article by McGregor and
associates1 on biomechanical testing of median sternotomy
closures performed on human cadavers. This work provides
the first measurement in the literature of chest wall forces on
coughing. One needs to know the magnitude of forces across
a sternotomy to test methods of sternotomy closure properly.
The norm in biomechanics is that a closure should be able to
withstand twice the potential maximum stresses. 
These first measurements of chest wall forces on coughing
are provided only indirectly. The article says that a force of
220 ± 40 N produced a lateral displacement of 1.85 ± 0.14
mm (ie, 260 N displaces 1.99 mm). Also, an intrathoracic
pressure of 63 ± 21 mm Hg displaced 2.14 ± 0.11 mm (ie, 42
mm Hg displaces 2.03 mm). Therefore, indirectly, a cough
generating 42 mm Hg produces a lateral force across a ster-
notomy of 260 N (~26 kg).
This work validates our mathematical model,2 which de-
scribes the force placed across a sternotomy closure. With our
model, where P is the distending pressure, r is the radius, l is
the height of the chest, and T is the force across the ster-
notomy,
T = rlP = 0.17m · 0.25m · 5.6 kPa = 238 N ~24 kg
the pressure of 42 mm Hg (~5.6 kPa) results in a predicted dis-
rupting force of 24 kg as compared with the measured value
of 26 kg. However, a normal cough reaches 100 mm Hg, pro-
ducing a force of 56 kg, whereas maximal coughing can gen-
erate a pressure of 300 mm Hg,3 producing a force of 168 kg.
We do not share McGregor and associates’ enthusiasm for
human cadavers. The problem in using whole human ster-
nums for biomechanical testing is in the wide biologic varia-
tion (eg, osteoporosis, metastases, age) in the samples and the
difficulty in quantifying this variation. Hence a large number
of samples is required to include bones of different quality.
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